Acute Myeloid Leukemia Clinical Trial
Official title:
Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia
Patients aged ≥70 years with acute myeloid leukemia (AML) have a poorer prognosis than those
aged 60 to 69 years. The poor outcome is the result of treatment-related toxicity in elderly
patients, owing to comorbidities, the greater possibility of other hematopoietic disorders,
and a biologically poor risk prognosis. Anthracycline- and cytarabine-based therapy,
administered for 3 and 7 days respectively (3 +7), remains the standard induction therapy
for this patient population. This approach improved survival compared with supportive care
(median, 5 vs. 3 months) for adults aged ≥ 65 years. However, the overall view has been that
the results of intensive chemotherapy in elderly patients remain poor. Although complete
remission (CR) rates of 40% to 80% can be achieved in highly selected populations, long-term
survival has been poor. Furthermore, most clinical trials have only enrolled patients with
an adequate performance status (PS).
Prognostic models have been developed from clinical trial data to predict the outcomes for
older patients. However; each model relies on chronologic age. Age is a surrogate measure
for both changes in tumor biology and patient characteristics. Understanding which patients
are likely to benefit from intensive therapies versus low-intensity therapies or supportive
care is critical. The definition of "fit" to undergo intensive induction therapy has not
been established, and the therapeutic choice is mainly determined by physician and patient
decision. In older patients, low-dose cytarabine (LD-AraC) has been demonstrated to be more
beneficial than best supportive care and hydroxyurea. The recent availability of new drugs
that could have an improved side effect profile and, in some cases, bioavailability might
offer future improvement for this patient population. In this setting, the investigators
have tended to consider, since 2007, patients aged ≥70 years as potential candidates for
alternative lower intensity therapy (LD-AraC, hypomethylating agents) even when they
presented in good physical condition.
The investigators goal was to determine whether age ≥ 70 years could represent a useful and
simple cut off for treatment decision-making in clinical practice and whether low-intensity
therapy could be an alternative therapeutic approach to intensive chemotherapy even for
patients aged ≥ 70 years who were theoretically "fit" (WHO /ECOG/ PS of ≤ 2).
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
| Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
| Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
| Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
| Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
| Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
| Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
| Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
| Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
| Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
| Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
| Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
| Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
| Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
| Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
| Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |